219 related articles for article (PubMed ID: 23256816)
1. The evolution of S100B inhibitors for the treatment of malignant melanoma.
Hartman KG; McKnight LE; Liriano MA; Weber DJ
Future Med Chem; 2013 Jan; 5(1):97-109. PubMed ID: 23256816
[TBL] [Abstract][Full Text] [Related]
2. Design of Inhibitors for S100B.
Markowitz J; Mackerell AD; Carrier F; Charpentier TH; Weber DJ
Curr Top Med Chem; 2005; 5(12):1093-108. PubMed ID: 16248785
[TBL] [Abstract][Full Text] [Related]
3. In vivo screening of S100B inhibitors for melanoma therapy.
Zimmer DB; Lapidus RG; Weber DJ
Methods Mol Biol; 2013; 963():303-17. PubMed ID: 23296618
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.
Markowitz J; Chen I; Gitti R; Baldisseri DM; Pan Y; Udan R; Carrier F; MacKerell AD; Weber DJ
J Med Chem; 2004 Oct; 47(21):5085-93. PubMed ID: 15456252
[TBL] [Abstract][Full Text] [Related]
5. Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography.
Charpentier TH; Wilder PT; Liriano MA; Varney KM; Zhong S; Coop A; Pozharski E; MacKerell AD; Toth EA; Weber DJ
Biochemistry; 2009 Jul; 48(26):6202-12. PubMed ID: 19469484
[TBL] [Abstract][Full Text] [Related]
6. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins.
Markowitz J; MacKerell AD; Weber DJ
Mini Rev Med Chem; 2007 Jun; 7(6):609-16. PubMed ID: 17584159
[TBL] [Abstract][Full Text] [Related]
7. Novel protein-inhibitor interactions in site 3 of Ca(2+)-bound S100B as discovered by X-ray crystallography.
Cavalier MC; Melville Z; Aligholizadeh E; Raman EP; Yu W; Fang L; Alasady M; Pierce AD; Wilder PT; MacKerell AD; Weber DJ
Acta Crystallogr D Struct Biol; 2016 Jun; 72(Pt 6):753-60. PubMed ID: 27303795
[TBL] [Abstract][Full Text] [Related]
8. The effects of CapZ peptide (TRTK-12) binding to S100B-Ca2+ as examined by NMR and X-ray crystallography.
Charpentier TH; Thompson LE; Liriano MA; Varney KM; Wilder PT; Pozharski E; Toth EA; Weber DJ
J Mol Biol; 2010 Mar; 396(5):1227-43. PubMed ID: 20053360
[TBL] [Abstract][Full Text] [Related]
9. Specificity of Molecular Fragments Binding to S100B versus S100A1 as Identified by NMR and Site Identification by Ligand Competitive Saturation (SILCS).
Young BD; Yu W; Rodríguez DJV; Varney KM; MacKerell AD; Weber DJ
Molecules; 2021 Jan; 26(2):. PubMed ID: 33450915
[TBL] [Abstract][Full Text] [Related]
10. Covalent small molecule inhibitors of Ca(2+)-bound S100B.
Cavalier MC; Pierce AD; Wilder PT; Alasady MJ; Hartman KG; Neau DB; Foley TL; Jadhav A; Maloney DJ; Simeonov A; Toth EA; Weber DJ
Biochemistry; 2014 Oct; 53(42):6628-40. PubMed ID: 25268459
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule Inhibitors of Ca(2+)-S100B Reveal Two Protein Conformations.
Cavalier MC; Ansari MI; Pierce AD; Wilder PT; McKnight LE; Raman EP; Neau DB; Bezawada P; Alasady MJ; Charpentier TH; Varney KM; Toth EA; MacKerell AD; Coop A; Weber DJ
J Med Chem; 2016 Jan; 59(2):592-608. PubMed ID: 26727270
[TBL] [Abstract][Full Text] [Related]
12. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma.
Lin J; Yang Q; Wilder PT; Carrier F; Weber DJ
J Biol Chem; 2010 Aug; 285(35):27487-27498. PubMed ID: 20587415
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells.
Lin J; Yang Q; Yan Z; Markowitz J; Wilder PT; Carrier F; Weber DJ
J Biol Chem; 2004 Aug; 279(32):34071-7. PubMed ID: 15178678
[TBL] [Abstract][Full Text] [Related]
14. Divalent metal ion complexes of S100B in the absence and presence of pentamidine.
Charpentier TH; Wilder PT; Liriano MA; Varney KM; Pozharski E; MacKerell AD; Coop A; Toth EA; Weber DJ
J Mol Biol; 2008 Sep; 382(1):56-73. PubMed ID: 18602402
[TBL] [Abstract][Full Text] [Related]
15. Calcium-binding properties of wild-type and EF-hand mutants of S100B in the presence and absence of a peptide derived from the C-terminal negative regulatory domain of p53.
Markowitz J; Rustandi RR; Varney KM; Wilder PT; Udan R; Wu SL; Horrocks WD; Weber DJ
Biochemistry; 2005 May; 44(19):7305-14. PubMed ID: 15882069
[TBL] [Abstract][Full Text] [Related]
16. Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells.
Yoshimura C; Miyafusa T; Tsumoto K
Bioorg Med Chem; 2013 Mar; 21(5):1109-15. PubMed ID: 23375094
[TBL] [Abstract][Full Text] [Related]
17. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulation of S100B protein to explore ligand blockage of the interaction with p53 protein.
Zhou Z; Li Y
J Comput Aided Mol Des; 2009 Oct; 23(10):705-14. PubMed ID: 19597941
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
[TBL] [Abstract][Full Text] [Related]
20. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
